A Phase 3 interventional study of AD-221 and AD-221A in Primary Hypercholesterolemia, sponsored by Addpharma Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-07-20.
Sponsored by Addpharma Inc. · Phase 3, Interventional, and Treatment
The purpose of this study is to evaluate the efficacy and safety of AD-221 and AD-221A
The purpose of this study is to evaluate the efficacy and safety of AD-221 and AD-221A in patients with primary hypercholesterolemia
1,238 studies on the registry are indexed under Hypercholesterolemia; 109 are open to participants now.
This study's enrollment of 290 is above the median of 99 across 991 interventional studies indexed under Hypercholesterolemia.
Browse Hypercholesterolemia studies →Addpharma Inc. is the lead sponsor of 56 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
AD-221, Placebo of AD-221A, AD-221B and AD-221C
Drug: AD-221
AD-221A, Placebo of AD-221, AD-221B and AD-221C
Drug: AD-221A
AD-221B, Placebo of AD-221, AD-221A and AD-221C
Drug: AD-221B
AD-221C, Placebo of AD-221, AD-221A and AD-221B
Drug: AD-221C
PO, Once daily(QD), 8 weeks
PO, Once daily(QD), 8 weeks
PO, Once daily(QD), 8 weeks
Also known as: Ezetimibe
PO, Once daily(QD), 8 weeks
Also known as: Atorvastatin
Low density lipoprotein cholesterol (LDL-C)
LDL-C change at Week 8
Time frame: Baseline, Week 8
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Addpharma Inc.